Vistagen Therapeutics, Inc. (VTGN) stock
VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3073% below fair value
$0.18+0.00 (+0.95%)
Close on Nov 13, 2026Market cap $8.01MP/E –Yield –
Vistagen Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Vistagen Therapeutics's total assets was $23.42M at Sep 30, 2026. For fiscal 2026 it was $48.56M, down 42.4% from the year before. Over ten years it grew 47.6% a year on average. The highest annual figure on record is $123.65M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $48.56M | -42.4% |
| FY2025 | Mar 31, 2025 | $84.34M | -31.8% |
| FY2024 | Mar 31, 2024 | $123.65M | +486.3% |
| FY2023 | Mar 31, 2023 | $21.09M | -71.7% |
| FY2022 | Mar 31, 2022 | $74.64M | -31.1% |
| FY2021 | Mar 31, 2021 | $108.28M | +1775.9% |
| FY2020 | Mar 31, 2020 | $5.77M | -58.8% |
| FY2019 | Mar 31, 2019 | $14.01M | +24.2% |
| FY2018 | Mar 31, 2018 | $11.28M | +203.8% |
| FY2017 | Mar 31, 2017 | $3.71M | +275.0% |
| FY2016 | Mar 31, 2016 | $989.80K | +267.0% |
| FY2015 | Mar 31, 2015 | $269.70K | +2.3% |
| FY2014 | Mar 31, 2014 | $263.70K | 0.0% |
| FY2013 | Mar 31, 2013 | $263.70K | -70.1% |
| FY2012 | Mar 31, 2012 | $881.50K | +172.4% |
| FY2011 | Mar 31, 2011 | $323.60K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | $23.42M | -71.1% |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $35.74M | -48.2% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $48.56M | -42.4% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $65.06M | -29.5% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $80.93M | -21.0% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $68.92M | -39.3% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $84.34M | -31.8% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $92.31M | -29.6% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $102.50M | +142.9% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $113.55M | +655.4% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $123.65M | +486.3% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $131.07M | +341.2% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $42.20M | +3.7% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $15.03M | -74.4% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $21.09M | -71.7% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $29.71M | -67.2% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $40.70M | -59.5% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $58.73M | -43.5% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $74.64M | -31.1% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $90.54M | -17.1% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $100.50M | +395.8% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $103.91M | +1584.9% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $108.28M | +1775.9% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $109.27M | +1949.8% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $20.27M | +132.0% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $6.17M | -52.4% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $5.77M | -58.8% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $5.33M | -29.1% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $8.74M | -1.7% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $12.95M | +56.8% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $14.01M | +24.2% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $7.52M | -47.2% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $8.89M | +239.6% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $8.26M | +238.8% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $11.28M | +203.8% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $14.24M | +142.4% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $2.62M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $2.44M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $3.71M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $5.88M | – |
See a number that looks wrong?